P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma

Volume 325:1608-1614		December 5, 1991		Number 23

P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma

HS Chan, G Haddad, PS Thorner, G DeBoer, YP Lin, N Ondrusek, H Yeger, and V Ling

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

Abstract

BACKGROUND AND METHODS. Multidrug resistance in chemotherapy for cancer is characterized by increased genetic expression of P-glycoprotein, which acts as an ATP-dependent drug-efflux pump. To determine whether P-glycoprotein levels are of prognostic value in such cases, we measured these levels immunohistochemically in a retrospective study of sequential tumor samples from 67 children with neuroblastoma. RESULTS. P-glycoprotein was not detected in pretreatment samples from either of the 2 patients with Stage I disease, any of the 21 with Stage II disease, or any of the 8 with Stage IVS disease, but it was detected in the samples from 1 of the 17 patients with Stage III disease (6 percent) and 12 of the 19 with Stage IV disease (63 percent). Of the 44 patients with nonlocalized neuroblastoma (Stage III, IVS, or IV), 26 of the 31 who were negative for P-glycoprotein had a complete response to primary treatment, as compared with 6 of the 13 who were positive for P-glycoprotein (84 percent vs. 46 percent, P = 0.0232 by Fisher's exact test). Log-rank analysis of outcome, with simultaneous stratification according to tumor stage and age, showed that the group that was negative for P-glycoprotein had significantly longer relapse-free survival (P = 0.0011) and overall survival (P = 0.0373) than the group that was positive. CONCLUSIONS. Expression of P-glycoprotein before treatment may predict the success or failure of therapy for nonlocalized neuroblastoma. Neuroblastoma may be a promising tumor to treat with anticancer drug therapy combined with a chemosensitizing agent capable of reversing P-glycoprotein-mediated multidrug resistance.

Source Information

Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada.

This article has been cited by other articles:

Seo, S., Hatano, E., Higashi, T., Hara, T., Tada, M., Tamaki, N., Iwaisako, K., Ikai, I., Uemoto, S. (2007). Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Predicts Tumor Differentiation, P-glycoprotein Expression, and Outcome after Resection in Hepatocellular Carcinoma. Clin. Cancer Res. 13: 427-433 [Abstract] [Full Text]
Filho, J. P. S., Correa, Z. M. S., Odashiro, A. N., Coutinho, A. B., Martins, M. C., Erwenne, C. M., Burnier, M. N. Jr (2005). Histopathological Features and P-glycoprotein Expression in Retinoblastoma. IOVS 46: 3478-3483 [Abstract] [Full Text]
Nakayama, K., Kanzaki, A., Terada, K., Mutoh, M., Ogawa, K., Sugiyama, T., Takenoshita, S., Itoh, K., Yaegashi, N., Miyazaki, K., Neamati, N., Takebayashi, Y. (2004). Prognostic Value of the Cu-Transporting ATPase in Ovarian Carcinoma Patients Receiving Cisplatin-Based Chemotherapy. Clin. Cancer Res. 10: 2804-2811 [Abstract] [Full Text]
Blanc, E., Goldschneider, D., Ferrandis, E., Barrois, M., Le Roux, G., Leonce, S., Douc-Rasy, S., Benard, J., Raguenez, G. (2003). MYCN Enhances P-gp/MDR1 Gene Expression in the Human Metastatic Neuroblastoma IGR-N-91 Model. Am. J. Pathol. 163: 321-331 [Abstract] [Full Text]
Ho, G-T, Moodie, F M, Satsangi, J (2003). Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?. Gut 52: 759-766 [Abstract] [Full Text]
Mealey, K. L., Barhoumi, R., Burghardt, R. C., Safe, S., Kochevar, D. T. (2002). Doxycycline Induces Expression of P Glycoprotein in MCF-7 Breast Carcinoma Cells. Antimicrob. Agents Chemother. 46: 755-761 [Abstract] [Full Text]
Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litchman, M., Sikic, B. I. (2001). A Phase I Trial of Doxorubicin, Paclitaxel, and Valspodar (PSC 833), a Modulator of Multidrug Resistance. Clin. Cancer Res. 7: 1221-1229 [Abstract] [Full Text]
Raggi, C. C., Maggi, M., Renzi, D., Calabrò, A., Bagnoni, M. L., Scaruffi, P., Tonini, G. P., Pazzagli, M., De Bernardi, B., Bernini, G., Serio, M., Orlando, C. (2000). Quantitative Determination of sst2 Gene Expression in Neuroblastoma Tumor Predicts Patient Outcome. J. Clin. Endocrinol. Metab. 85: 3866-3873 [Abstract] [Full Text]
Vigano, C., Margolles, A., van Veen, H. W., Konings, W. N., Ruysschaert, J.-M. (2000). Secondary and Tertiary Structure Changes of Reconstituted LmrA Induced by Nucleotide Binding or Hydrolysis. A FOURIER TRANSFORM ATTENUATED TOTAL REFLECTION INFRARED SPECTROSCOPY AND TRYPTOPHAN FLUORESCENCE QUENCHING ANALYSIS. J. Biol. Chem. 275: 10962-10967 [Abstract] [Full Text]
Canete, A., Navarro, S., Bermudez, J., Pellin, A., Castel, V., Llombart-Bosch, A. (2000). Angiogenesis in Neuroblastoma: Relationship to Survival and Other Prognostic Factors in a Cohort of Neuroblastoma Patients. JCO 18: 27-27 [Abstract] [Full Text]
Raggi, C. C., Bagnoni, M. L., Tonini, G. P., Maggi, M., Vona, G., Pinzani, P., Mazzocco, K., De Bernardi, B., Pazzagli, M., Orlando, C. (1999). Real-Time Quantitative PCR for the Measurement of MYCN Amplification in Human Neuroblastoma with the TaqMan Detection System. Clin. Chem. 45: 1918-1924 [Abstract] [Full Text]
Maris, J. M., Matthay, K. K. (1999). Molecular Biology of Neuroblastoma. JCO 17: 2264-2264 [Abstract] [Full Text]
Vasudevan, S., Tsuruo, T., Rose, D. R. (1998). Mode of Binding of Anti-P-glycoprotein Antibody MRK-16 to Its Antigen. A CRYSTALLOGRAPHIC AND MOLECULAR MODELING STUDY. J. Biol. Chem. 273: 25413-25419 [Abstract] [Full Text]
Desrayaud, S., De Lange, E. C.�M., Lemaire, M., Bruelisauer, A., De Boer, A. G., Breimer, D. D. (1998). Effect of the Mdr1a P-Glycoprotein Gene Disruption on the Tissue Distribution of SDZ PSC 833,�a Multidrug Resistance-Reversing Agent, in Mice. J. Pharmacol. Exp. Ther. 285: 438-443 [Abstract] [Full Text]
Horton, J. K., Thimmaiah, K. N., Altenberg, G. A., Castro, A. F., Germain, G. S., Gowda, G. K., Houghton, P. J. (1997). Characterization of a Novel Bisacridone and Comparison with PSC 833�as a Potent and Poorly Reversible Modulator of P-Glycoprotein. Mol. Pharmacol. 52: 948-957 [Abstract] [Full Text]
Sundseth, R., Macdonald, G., Ting, J., King, A. C. (1997). DNA Elements Recognizing NF-Y and Sp1 Regulate the Human Multidrug-Resistance Gene Promoter. Mol. Pharmacol. 51: 963-971 [Abstract] [Full Text]
Sonveaux, N., Shapiro, A. B., Goormaghtigh, E., Ling, V., Ruysschaert, J.-M. (1996). Secondary and Tertiary Structure Changes of Reconstituted P-glycoprotein. A FOURIER TRANSFORM ATTENUATED TOTAL REFLECTION INFRARED SPECTROSCOPY ANALYSIS. J. Biol. Chem. 271: 24617-24624 [Abstract] [Full Text]
Duhem, C., Ries, F., Dicato, M. (1996). What does Multidrug Resistance (MDR) Expression Mean in the Clinic?. The Oncologist 1: 151-158 [Abstract] [Full Text]
Mesa-Tejada, R., Johnston, J. M., Duensing, S., Ganser, A., Atzpodien, J., Baldini, N., Bertoni, F. (1996). P-Glycoprotein and Multidrug Resistance. NEJM 334: 1335-1337 [Full Text]
TAKESHITA, H., GEBHARDT, M. C., SPRINGFIELD, D. S., KUSUZAKI, K., MANKIN, H. J. (1996). Experimental Models for the Study of Drug Resistance in Osteosarcoma: P-Glycoprotein-Positive, Murine Osteosarcoma Cell Lines. JBJS 78: 366-75 [Abstract] [Full Text]
Norris, M. D., Bordow, S. B., Marshall, G. M., Haber, P. S., Cohn, S. L., Haber, M. (1996). Expression of the Gene for Multidrug-Resistance-Associated Protein and Outcome in Patients with Neuroblastoma. NEJM 334: 231-238 [Abstract] [Full Text]
Zhang, J.-T., Lee, C. H., Duthie, M., Ling, V. (1995). Topological Determinants of Internal Transmembrane Segments in P-glycoprotein Sequences. J. Biol. Chem. 270: 1742-1746 [Abstract] [Full Text]
Ferry, D R, Kerr, D J (1994). Multidrug resistance in cancer. BMJ 308: 148-149 [Full Text]

Comments and questions? Please contact us.